Zacks Rating on Catalent (CTLT)

Catalent (CTLT) : The consensus on Catalent (CTLT) based on 8 analyst recommendation on the company stock is 2.25, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 5 which endorses a Strong Sell on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Catalent (CTLT) : 5 Wall Street analysts covering Catalent (CTLT) believe that the average level the stock could reach for the short term is $26.5. The maximum price target given is $31 and the minimum target for short term is around $23, hence the standard deviation is calculated at $2.87.


Shares of Catalent, Inc. rose by 2.45% in the last five trading days and 4.29% for the last 4 weeks. Catalent, Inc. has dropped 11.2% during the last 3-month period . Year-to-Date the stock performance stands at 2%. Catalent (NYSE:CTLT): stock turned positive on Tuesday. Though the stock opened at $24.8, the bulls momentum made the stock top out at $25.81 level for the day. The stock recorded a low of $24.74 and closed the trading day at $25.53, in the green by 3.36%. The total traded volume for the day was 1,265,010. The stock had closed at $24.7 in the previous days trading.

Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *